Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study

埃索美拉唑 克拉霉素 医学 内科学 幽门螺杆菌 阿莫西林 胃肠病学 不利影响 随机对照试验 抗生素 微生物学 生物
作者
Jung Won Lee,Nayoung Kim,Jong-Chan Lee,So Young Jo,Dong Ho Lee
出处
期刊:Helicobacter [Wiley]
卷期号:29 (5): e13143-e13143 被引量:10
标识
DOI:10.1111/hel.13143
摘要

BACKGROUND: Treatment with potassium-competitive acid blockers has shown acceptable efficacy in Helicobacter pylori eradication. In regions like Korea, where the clarithromycin resistance rate is high, alternative combinations like non-bismuth quadruple therapies have shown favorable results. This study compared the outcomes of sequential eradication therapy with new potassium-competitive acid blocker tegoprazan and conventional esomeprazole-containing sequential therapy. MATERIALS AND METHODS: Patients with Helicobacter pylori (H. pylori) infection were consecutively recruited. Patients were allocated to either an esomeprazole-containing sequential or a tegoprazan-containing sequential therapy group. Sequential therapy comprised esomeprazole (40 mg) or tegoprazan (50 mg) plus amoxicillin (1000 mg) twice daily for the initial 5 days, followed by esomeprazole (40 mg) or tegoprazan (50 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice daily for the remaining 5 days. Eradication rate, compliance, and adverse events were recorded. RESULTS: A total of 406 patients with H. pylori infection were enrolled in the trial and analyzed per protocol. Eradication rate by intention-to-treat and per-protocol was 83.8% (95% confidence interval [CI]: 78.7-88.9) for esomeprazole-containing sequential therapy, and 87.1% (95% CI: 82.5-91.8) for tegoprazan-containing sequential therapy, with no statistical significance (p = 0.399). Additionally, there was no statistically significant difference in treatment compliance between the two groups. Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; p = 0.022). CONCLUSION: Tegoprazan-containing 10-day sequential eradication treatment demonstrated similar eradication efficacy compared to esomeprazole-containing treatment, even in regions with high antimicrobial resistance, such as Korea. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06382493.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
SciGPT的应助被听安采纳,获得10
2秒前
2秒前
笑点低明轩完成签到,获得积分20
2秒前
3秒前
MzzzzX完成签到 ,获得积分10
5秒前
5秒前
大个的应助被张奕泽采纳,获得10
6秒前
hony发布了新的文献求助20
6秒前
7秒前
本喵不怂完成签到,获得积分20
8秒前
领导范儿的应助被余子文采纳,获得10
9秒前
科研通AI6.2的应助被吱吱采纳,获得10
9秒前
9秒前
zhyzzz发布了新的文献求助10
9秒前
sunxiaojun发布了新的文献求助10
9秒前
温凉发布了新的文献求助10
9秒前
9秒前
12秒前
12秒前
慕青的应助被liugm采纳,获得10
12秒前
小二郎的应助被哇哇哇采纳,获得10
13秒前
th1e发布了新的文献求助10
13秒前
Philo完成签到,获得积分10
14秒前
听安发布了新的文献求助10
15秒前
15秒前
Forward发布了新的文献求助10
15秒前
16秒前
傲娇钢笔完成签到 ,获得积分10
16秒前
一只咸鱼完成签到 ,获得积分10
16秒前
开心的畅畅完成签到 ,获得积分10
17秒前
17秒前
酷波er的应助被hbuiio采纳,获得10
18秒前
cuipi发布了新的文献求助10
18秒前
CipherSage的应助被Twinkle采纳,获得10
19秒前
香蕉觅云的应助被erdongsir采纳,获得10
19秒前
20秒前
张奕泽发布了新的文献求助10
20秒前
21秒前
小巧慕蕊完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189472
求助须知:如何正确求助?哪些是违规求助? 9576774
关于积分的说明 21849709
捐赠科研通 7787422
什么是DOI,文献DOI怎么找? 3435600
关于科研通互助平台的介绍 2559782
邀请新用户注册赠送积分活动 2482552